## In the Claims

- 1. (cancelled).
- 2. (previously cancelled).
- 3. (currently amended) A  $\underline{\text{method}}$  composition according to Claim  $\underline{32}$   $\pm$  wherein the amphoteric surfactant is a balanced amphoteric surfactant.
  - 4. (cancelled).
- 5. (currently amended) A <u>method</u> <del>composition</del> according to Claim 32 1 wherein the amphoteric surfactant comprises disodium cocoamphodiacetate.
  - 6-8. (previously cancelled).
- 9. (currently amended) A <u>method</u> <del>composition</del> according to Claim <u>32</u> + wherein the composition further comprises a corticosteroid.
  - 10. (previously cancelled).
- 11. (currently amended) A <u>method</u> composition according to Claim 32 4 wherein the composition is an oil-in-water emulsion.
- 12. (currently amended) A  $\underline{\text{method}}$  composition according to Claim 32  $\pm$  wherein the composition is a foam.
- 13. (previously amended) A composition consisting
  essentially of:

sorbitan tristearate or non-ionic emulsifying wax 0.5 to 5% w/v

glycerol monostearate	0.5 to 5% w/v
light liquid paraffin	1 to 20% w/v
white soft paraffin	1 to 10% w/v
iso propyl myristate	0.5 to 5% w/v
polar drug	0.1 to 20% w/v
disodium edetate	0.01 to 1% w/v
amphoteric surfactant	0.1 to 10% w/v
alkoxylated cetyl alcohol	0.1 to 10% w/v
triclosan	0.01 to 1% w/v
benzyl alcohol	0.01 to 1% w/v
purified water	to 100% of the emulsion

- 14. (previously cancelled).
- 15. (cancelled).
- 16. (previously cancelled)
- 17. (currently amended) A method composition as in Claim 32 l-for treating a skin disease or wherein said skin condition is selected from the group consisting of atopic dermatitis, contact sensitivity, psoriasis, drug sensitivity reactions, apthous ulcers, Behcet's syndrome, pemphigus, urticaria, urticaria pigmentosa, pyroderma gangrenosum, chronic skin ulcers, ulcers associated with Crohn's disease, burns, insect stings/bites, herpetic infections, systemic sclerosis, morphoea, dermal nodular

fibrosis, and sunburn by applying said composition to the skin of an individual affected by the disease or condition.

- 18-20. (previously cancelled).
- 21-23. (cancelled).
- 24-27. (previously cancelled).
- 28. (currently amended) A method as in Claim 32 wherein said composition is The composition of Claim 1 being packaged in a tube, tub, bottle or pressurised aerosol container.
  - 29-30. (previously cancelled).
  - 31. (cancelled).
- 32. (newly added) A method for treating a skin condition of a human patient, comprising:
- (a) providing an aqueous and oil phase composition comprising about 1-5% w/v of an amphoteric surfactant, about 0.5-4% w/v of an alkoxylated cetyl alcohol, and about 1-10% w/v of a polar drug selected from the group consisting of sodium cromoglycate and nedocromil sodium; and
- (b) applying said composition to the patient's skin.
- 33. (newly added) A method as in claim 32 wherein said alkoxylated cetyl alcohol is selected from the group